Quantitative Chemotherapeutic Profiling of Gynecologic Cancer Cell Lines Using Approved Drugs and Bioactive Compounds

Kirill Gorshkov*, Ni Sima*, Wei Sun*, Billy Lu*, Wei Huang*, Jameson Travers*, Carleen Klumpp-Thomas*, Samuel G. Michael*, Tuan Xu*, Ruili Huang*, Emily M. Lee*, Xiaodong Cheng† and Wei Zheng

*National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Bethesda, MD 20892, USA; †Department of Gynecologic Oncology, Women’s Reproductive Health Laboratory of Zhejiang Province, Women’s Hospital, School of Medicine, Zhejiang University, 866 Yuhangtang Rd, Hangzhou 310058, PR China

Abstract
Heterogeneous response to chemotherapy is a major issue for the treatment of cancer. For most gynecologic cancers including ovarian, cervical, and placental, the list of available small molecule therapies is relatively small compared to options for other cancers. While overall cancer mortality rates have decreased in the United States as early diagnoses and cancer therapies have become more effective, ovarian cancer still has low survival rates due to the lack of effective treatment options, drug resistance, and late diagnosis. To understand chemotherapeutic diversity in gynecologic cancers, we have screened 7914 approved drugs and bioactive compounds in 11 gynecologic cancer cell lines to profile their chemotherapeutic sensitivity. We identified two HDAC inhibitors, mocetinostat and entinostat, as pan-gynecologic cancer suppressors with IC50 values within an order of magnitude of their human plasma concentrations. In addition, many active compounds identified, including the non-anticancer drugs and other compounds, diversely inhibited the growth of three gynecologic cancer cell groups and individual cancer cell lines. These newly identified compounds are valuable for further studies of new therapeutics development, synergistic drug combinations, and new target identification for gynecologic cancers. The results also provide a rationale for the personalized chemotherapeutic testing of anticancer drugs in treatment of gynecologic cancer.

Introduction
The five main gynecologic cancers, including ovarian, cervical, uterine, vaginal, and vulvar, correspond to 12% (94,990) of new female cancer diagnoses annually in the United States [1]. Of those, uterine endometrial, ovarian, and cervical are the most prevalent, with ovarian being the fifth leading cause of death from cancer for females in the United States [2]. In 2018, it is estimated that there will be 22,240 new ovarian cancer cases (2.5% of all female cancer cases) and 14,070 ovarian cancer deaths (5% of all female cancer deaths) [2]. The high case-to-fatality ratio exhibited in ovarian cancer can be attributed to late-stage diagnosis, lack of effective drug therapies, and tumor heterogeneity. Thus, it is important to discover new therapeutics for ovarian cancers that can improve survival in late-stage ovarian cancer patients.

While ovarian cancer is usually diagnosed at later stages of disease, resulting in a low 5-year survival of 29% for distant-stage disease, cervical cancer is typically diagnosed at early stages and thus has more favorable outcomes [2]. However, in 2017, it was found that cervical
cancer death rates have been underestimated due to the prior inclusion of women who have had hysterectomies [3]. Additionally, and importantly, this study identified a large disparity in race, where black women were dying at a 77% higher rate (10.1 in 100,000 vs. 5.4 in 100,000) while white women were dying at a 47% (4.7 in 100,000 vs. 3.2 in 100,000) higher rate than previously calculated without the hysterectomy exclusion criteria. Thus, cervical cancer remains a critical driver of mortality in women.

Placental cancers, or gestational trophoblastic disease (GTD) choriocarcinomas, are another type of gynecologic cancer. Gestational carcinomas arise from the fetal-derived layer of cells called the trophoblast that surrounds an embryo [4] and are rare, with an incidence ranging from approximately 1 in 15,000 to 50,000 [4,5]. A combination of surgery, radiation, and chemotherapy is the common treatment modality for gynecologic cancers [6].

There is currently a set of standard anticancer drugs used in the clinic to treat gynecologic cancers. For ovarian and cervical cancer, these include chemotherapy agents gemcitabine, cisplatin, and doxorubicin as well as targeted therapeutics such as topotecan, a topoisomerase inhibitor, and bevacizumab, a monoclonal antibody directed against vascular endothelial growth factor [7,8]. While cisplatin is the most active and effective drug for ovarian cancer, resistance quickly develops, and many patients die with platinum-resistant cancer [9]. For placental cancer, methotrexate, a dihydrofolate reductase inhibitor, or Actinomycin D, a transcription inhibitor, is often used [10]. Combination therapy is common with a platinum-based compound given along with paclitaxel, a tubulin inhibitor [11,12]. In addition to the compounds above, vaccine, antibody, and cell-based immunotherapies are being considered as treatments for gynecologic and other solid tumor cancers [13]. Despite great progress in developing novel solutions to improve the therapeutic outcome for treatment of gynecologic cancers, more work needs to be done to understand the varied responses to different drugs in patients with different gynecologic cancers [14].

To understand the diversity in compound efficacy across gynecologic cancers within individual cancer groups and identify new active compounds, we have screened 7914 compounds consisting of approved drugs and bioactive compounds using a quantitative high-throughput screening (qHTS) method against 11 unique gynecologic cancer cell lines derived from ovarian, cervical, and placental cancers. The results were analyzed to profile the chemotherapeutic activities of compounds against these gynecologic cancer cell lines. Our data demonstrate the commonality and diversity in responses of gynecologic cancers to the anticancer agents. We have also identified a group of non-anticancer compounds with anti-gynecologic cancer activities that can be further studied for target identification and drug development.

### Results

#### Assay Development

To determine the inhibitory effects of approved drugs and bioactive compounds on the common gynecologic cancer cell lines, 11 cell lines including 7 ovarian cancer lines (CAOV-3, SK-OV-3, SW 626, ES-2, PA-1, TOV-21G), 3 cervical cancer lines (HeLa, Ca Ski, and C-33 A), and 2 placentation cancer lines (JAR, JEG-3) were used in the drug repurposing screen with HEK 293T cells as a control line to determine selectivity index of anticancer compounds (SI) [15–17] (Table 1; Supplementary Figure 1). The optimal assay conditions for the ATP content cell viability assay were determined in the ovarian PA-1 (Figure 1A, B and Supplementary Figure 2A-C) and CAOV-3 (Figure 1C, D and Supplementary Figure 2D-F) cell lines. Based on the assay optimization results, we used 1000 cells per well plated in 1536-well plates and a 48-hour incubation with compounds. The control compound activities (IC_{50}) of adriamycin and curcubitacin B reached the steady state at this assay condition. Other standard-of-care (SOC) anticancer drugs examined during optimization included paclitaxel and topotecan [18] (Supplementary Figure 3A-F). Adriamycin and curcubitacin B were designated as the positive control compounds in the subsequent screens (Supplementary Figure 3G, H).

### High-Throughput Compound Screening and Hit Confirmation

Following optimization, we next screened a collection of 7914 compounds including the FDA-approved drugs and bioactive compounds in 11 cancer cell lines shown in Table 1 (Supplementary Figure 1; Pubchem AID 1345084). From the primary screen, 256 hits were identified with the criteria of IC_{50} less than 10 μM, efficacy greater than 50%, and three-fold greater selectivity over the HEK 293T cells. From the primary screen, the signal-to-basal ratio was

### Table 1. Cell Lines Used in the OBGYN Cancer Chemotherapeutic Profiling

| Cell Line | ATCC Catalog Number | Tissue Origin | Cancer Type or Cell Type | Mutations | Doubling time (+, days) |
|-----------|---------------------|---------------|--------------------------|-----------|------------------------|
| CAOV-3    | HTB-75              | Ovary         | Adenocarcinoma           |           |                        |
| SK-OV-3   | HTB-77              | Ovary         | Adenocarcinoma           |           |                        |
| SW 626    | HTB-78              | Ovary         | Grade III, adenocarcinoma|           |                        |
| ES-2      | CRL-1978            | Ovary         | Clear cell carcinoma     |           |                        |
| PA1       | CRL-1572            | Ovary         | Teratocarcinoma          |           |                        |
| TOV-21G   | CRL-11730           | Ovary         | Grade 3, stage III, primary malignant adenocarcinoma; clear cell carcinoma | TP53      |                        |
| TOV-112D* | CRL-11731           | Ovary         | adenocarcinoma; endometrioid carcinoma | CTNNB1    |                        |
| OV-90     | CRL-11732           | Ovary         | Grade 3, stage IIIC, malignant papillary serous adenocarcinoma; | BRAF      |                        |
| HeLa      | CCL-2               | Cervix        | Adenocarcinoma           |           |                        |
| Ca Ski    | CRL-1550            | Cervix        | Epidermoid Carcinoma     |           |                        |
| C-33 A    | HTB-31              | Cervix        | Carcinoma                |           |                        |
| JAR       | HTB-144             | Placenta      | Choriocarcinoma          |           |                        |
| JEG-3     | HTB-36              | Placenta      | Choriocarcinoma          |           |                        |
| HEK 293 T | CRL-3216            | Embryonic kidney | Epithelial, noncancerous |           |                        |

* These cell lines were used only in the primary screen.

† These cell lines were added for the confirmation screen.
9.30, coefficient of variation was 13.2% and Z' factor was 0.69 in the PA-1 cell line. For the CAOV-3 cell line, the signal-to-basal ratio was 9.86, coefficient of variation was 11.3%, and Z' factor was 0.71. Among the primary hits tested in a follow-up screen (Pubchem AID 1345085), 205 compounds were confirmed using criteria of IC₅₀ less than 30 μM, efficacy greater than 70%, and five-fold greater selectivity over HEK cells. A group of hits that were toxic to both cancer cells and HEK 293T cells was designated as the pan-toxic compounds (Supplementary Figure 4 and Table 2). The pan-cytotoxic compounds included panobinostat[19], givinostat[20], irestatin 9389[21], NVP-BGT226[22], vorinostat[23], TG-46[24], NVP-TAE684[25], and ponatinib[26]. The concentration-response curves for panobinostat (IC₅₀ = 2.76 ± 1.98 μM; SI >100), a DNA intercalator and common drug for GTD, and fedratinib[33] (IC₅₀ = 13.1 ± 7.51 μM; SI >100), a JAK2 inhibitor (Supplementary Figure 6 and Table 3). The ovarian and placental cancer cell line selective inhibitors included actinomycin D[32] (IC₅₀ = 0.78 ± 0.222 μM; SI >100), a JAK2 inhibitor, and CCT137690[34] (IC₅₀ = 20.0 ± 7.02 μM; SI >100), an Aurora kinase inhibitor (Supplementary Figure 7 and Table 3). The cervical cancer selective inhibitory compounds found in our study were also active for the ovarian cancer cells.

Chemotherapeutic Diversity Among 11 Gynecologic Cancer Cell Lines

To further evaluate the 205 confirmed compounds in the 11 gynecologic cancer cell lines, we focused on the tissue types of these cancer cell lines to analyze the selectivity and diversity of compound activity. This analysis revealed two compounds, mocetinostat[27–29] (IC₅₀ = 2.76 ± 1.98 μM; SI >100) and entinostat[30,31] (IC₅₀ = 7.11 ± 6.62 μM; SI >100), both class I HDAC inhibitors and in clinical trials, as pan-killers of all three cancer cell groups (Figures 2A, 3, and Table 3). The ovarian and placental cancer cell line selective inhibitors included actinomycin D[32] (IC₅₀ = 0.78 ± 0.222 μM; SI >100), a DNA intercalator and common drug for GTD, and fedratinib[33] (IC₅₀ = 13.1 ± 7.51 μM; SI >100), a JAK2 inhibitor (Supplementary Figure 6 and Table 3). The ovarian and cervical cancer cell line selective inhibitors included TG-89[24] (IC₅₀ = 11.2 ± 7.28 μM; SI >100), a JAK2 inhibitor, and CCT137690[34] (IC₅₀ = 20.0 ± 7.02 μM; SI >100), an Aurora kinase inhibitor (Supplementary Figure 7 and Table 3). The individual cancer types, the top ovarian cancer cell selective inhibitor was fostamatinib[35] (IC₅₀ = 6.24 ± 4.06 μM; SI >100), a Syk kinase inhibitor (Supplementary Figure 8A-D and Table 3). The top placental cancer line inhibitor was berberine[36,37] (IC₅₀ = 4.41 ± 0.662 μM; SI >100), an anti-parasitic alkaloid targeting Complex I of the mitochondrial respiratory chain and AP-1 machinery (Supplementary Figure 8E-H and Table 3). The cervical cancer selective inhibitory compounds found in our study were also active for the ovarian cancer cells.
Table 2. Hits with HEK293T Toxicity >50%, IC_{50} <30 \mu M, and CCL Efficacy >70%.

| Compound Name | FDA Approved | Compound Class | Target | Average SI | Average IC_{50} (\mu M) |
|---------------|--------------|----------------|--------|------------|------------------------|
| Panobinostat  | Yes; 2015    | Antineoplastic; hydroxamate | Pan-HDAC | 0.92 ± 0.57 | 0.355 ± 0.268 |
| Givinostat    | No; in clinical trials | Antineoplastic; hydroxymate | Class I and II HDAC | 1.74 ± 1.25 | 3.50 ± 3.88 |
| Irestatin 9389 | No | Antineoplastic; diazole | IRE1 endonuclease | 0.51 ± 0.20 | 3.52 ± 3.12 |
| NVP-BGT226    | No; in clinical trials | Antineoplastic; imidazole quinoline | PI3K/mTOR | 0.20 ± 0.26 | 5.34 ± 6.56 |
| Vorinostat    | Yes; 2006    | Antineoplastic; hydroxymate | HDAC | 3.72 ± 2.24 | 5.50 ± 4.17 |
| TG-46         | No | Antineoplastic | JAK2 | 10.5 ± 22.1 | 9.59 ± 6.87 |
| NVP-TAE684    | No | Antineoplastic | ALK | 4.87 ± 7.61 | 15.7 ± 10.0 |
| Ponatinib     | Yes; 2012    | Antineoplastic; pyridazine | Bcr-Abl | 3.56 ± 4.85 | 15.9 ± 9.07 |

Confirmation of HEK 293T toxicity Using an Independent Screen [84]

| Compound Name | IC_{50} Efficacy (%) Curve Class | Independent Screen | IC_{50} Efficacy (%) Curve Class |
|---------------|----------------------------------|---------------------|----------------------------------|
| Panobinostat  | 0.21 82.6 -1.17 Confirmed toxic | 0.162 85.5 -1.1 |
| Givinostat    | 2.91 65.6 -1.1 Confirmed toxic | 1.11 112 -1.1 |
| Irestatin 9389 | 1.34 102 -1.1 Not toxic | |
| NVP-BGT226    | 0.258 106 -1.1 Confirmed toxic | 0.0145 115 -1.1 |
| Vorinostat    | 11.3 64.7 -1.93 Confirmed toxic | 4.09 80.2 -1.2 |
| TG-46         | 19.4 75.6 -2.1 Confirmed toxic | 8.44 89.7 -2.15 |
| NVP-TAE684    | 23.4 91.8 -2.1 Confirmed toxic | 3.65 126 -2.1 |
| Ponatinib     | 19.9 92 -2.1 Confirmed toxic | 0.811 92.6 -1.1 |

Table depicting compounds that are toxic (EFFIC2ACY >70%) to all cell lines including HEK293T. Table shows compound name, FDA approval status, compound class, target, average selectivity, and average IC_{50} (\mu M).

Figure 2. Chemotherapeutic diversity in cell line killing. (A) Venn diagram illustrating the number of selective compounds (efficacy >70%, IC_{50} <30 \mu M, SI >5) in each cancer group. Overlapping circles and number inset indicate number of compounds which are shared between the groups. Compound must be active in at least four of the six ovarian cancer cell lines to be considered ovarian cancer cell line selective. (B) Log scale bar graph depicting the number of compounds which had an SI >5 for each cancer line panel. Heat maps depicting the Log (SI) value for compounds active in at least one cell line with selectivity greater than five-fold for ovarian (C), cervical (D), and placental (E) cancer panels. Black boxes indicate no selectivity could be determined for that cell line.
Given that we included different numbers of cell lines for each of three gynecologic cancer groups, we assessed the number of compounds whose SI was greater than five (Figure 2B) in each group. Interestingly, while there were only 2 placental lines included in the study, 13 compounds reached an SI of 5 or greater in this group. Four compounds killed all three cervical cancer lines selectively, and only one compound, fedratinib, selectively killed all six ovarian cancer lines. Fedratinib, one of the ovarian and cervical CCL selective inhibitors, has completed two Phase I clinical trials for solid tumors (ClinicalTrials.gov Identifier: NCT01836705; NCT01585623) but is not an FDA-approved drug. The heat maps for each cancer tissue group provided a high-level view of the SI for each compound that fulfilled the criteria (Figure 2C-E). These maps reveal that PA-1, TOV-21-G, and HeLa cells, the faster growing lines (Table 1), were more sensitive for qHTS as the compounds exhibited higher inhibitory activities.

**Single Cancer Cell Line Selective Compounds**

In addition to finding compounds with general antineoplastic activity, the selective inhibitory activities of compounds to individual cell lines were evaluated. We identified five compounds with selective inhibitory activities for PA-1, two compounds for TOV-21-G, and four compounds for HeLa (Figure 4 and Table 4). As mentioned above, these cell lines were the most susceptible to anticancer compounds because of their fast cell growth rates. We did not find selective compounds that only exhibited inhibitory activities to any of the eight remaining cancer cell lines individually. Since we performed a detailed analysis of the compounds’ concentration-response curves,
it helps to illustrate the significant differences in efficacy and potency between these lines and the control HEK 293T line. For PA-1, mycophenolate mofetil [38], an antifungal, was the most potent PA-1 suppressor (IC₅₀ = 0.631 μM; SI >100). Neratinib [39] (IC₅₀ = 0.619 μM; SI >100), an FDA-approved epidermal growth factor receptor (EGFR) inhibitor, and milciclib [40] (IC₅₀ = 0.0897 μM (SI = 50.1)), a CDK inhibitor, were the two most potent TOV-21-G inhibitors. The top HeLa suppressor was LY2874455 [41] (IC₅₀ = 0.240; SI = 38.8) μM, a pan-FGFR inhibitor.

### Top Clinically Relevant Compounds

The results from our qHTS gynecologic cancer profiling revealed a diverse set of compounds with potencies ranging from the nanomolar to micromolar and different selectivity among three types of cancer tissues. We wanted to highlight these nanomolar compounds which may be useful to researchers and clinicians alike as these are the ones to micromolar and different selectivity among three types of cancer tissues. We wanted to highlight these nanomolar compounds which may be useful to researchers and clinicians alike as these are the ones to micromolar and different selectivity among three types of cancer tissues. We wanted to highlight these nanomolar compounds which may be useful to researchers and clinicians alike as these are the ones among 11 cancer cell lines tested (Supplementary Figure 9).

The average IC₅₀ for panobinostat for the ovarian, cervical, and placental lines in our study is 0.343, 0.224, and 0.516 μM, respectively. The IC₅₀ average for all cell lines is 0.719 μM, within the range of the intravenous, but not oral, Cmax values.

Bortezomib, a 20S proteasome inhibitor, exhibited an average IC₅₀ of 0.150 μM with good efficacy in 8 of the 11 cancer cell lines excluding SKOV-3, HeLa, and JAR. Its average IC₉₀ was 0.218 μM, well within the intravenous dose Cmax of 580 nM [44]. Elesclomol, a ROS inducer, was active in six cell lines with an IC₅₀ of 0.173 μM and an IC₉₀ of 0.283 μM. The Cmax of elesclomol in a clinical trial ranged from 1.32 to 12.84 μM with doses of 44 to 438 mg/m² [45]. Thus, elesclomol is a good clinically relevant candidate for gynecologic cancers. Actinomycin D, mentioned previously as an FDA-approved drug for multiple cancers, exhibited nanomolar potency against six cell lines as well while maintaining high selectivity for cancer cell lines. The average IC₅₀ for Actinomycin D in our study against ES-2, CAOV3, PA-1, TOV-21-G, SK-OV-3, and Ca Ski was 512 nM, while the Cmax in a pediatric population can range from 4 to 97.2 nM after 15 minutes of exposure to the drug [46]. Another trial measured a Cmax ranging from 2.5 to 79 nM, indicating that the IC₉₀ identified in our study is several-fold above what can be achieved in human blood plasma [47]. The extended comparison of IC₉₀ to Cmax values for the most promising clinical candidates from Supplementary Figure 9 is presented in Table 5.

### Discussion

Heterogeneous responses in gynecologic cancers to chemotherapeutic drugs make it challenging to predict the drug’s clinical effectiveness.

---

**Table 3. Diversity List of the Most Effective Compounds with IC₉₀ <30 μM and CCL Efficacy >70%**

| Compound Name                  | FDA Approved | Compound Class          | Target                        | Average SI | Average IC₅₀ (μM) |
|--------------------------------|--------------|--------------------------|-------------------------------|-----------|------------------|
| Pan-GYN Cancer Cell Line Killer|              |                          |                               |           |                  |
| Mocetinostat                   | No; clinical trials | Antineoplastic; 2-aminobenzamide | Class 1 HDAC | >100 | 2.76 ± 1.98 |
| Entinostat                     | No; clinical trial | Antineoplastic; 2-aminobenzamide | Class 1 HDAC | >100 | 7.11 ± 6.62 |
| Ovarian + Placental Cancer Cell Line Killer | | | | | |
| Actionomicyn D                 | Yes; 1964    | Antibiosis; antineoplastic; multiple cancers | DNA intercalator | >100 | 0.78 ± 0.222 |
| Fedratinib                     | No; clinical trials | Antineoplastic | JAK2 | >100 | 13.1 ± 7.51 |
| Ovarian + Cervical Cancer Cell Line Killer | | | | | |
| TG-89                          | No           | Antineoplastic            | JAK2                         | >100 | 11.2 ± 7.28 |
| CCT137690                      | No           | Antineoplastic            | Aurora kinase                | >100 | 20.0 ± 7.02 |
| Ovarian Cell Line Killer       |              |                          |                               |           |                  |
| Fontaminib                     | No; clinical trials | Pluripotent; Antineoplastic | Syk | >100 | 6.24 ± 4.06 |
| AZ-960                         | No           | NA                       | JAK2                         | >100 | 12.0 ± 7.75 |
| WZ3146                         | No           | NA                       | EGFR                         | >100 | 12.3 ± 8.52 |
| AMG-Tie2-1                     | No           | RTK inhibitor             | Tie2                         | >100 | 15.9 ± 9.71 |
| TAE226                         | No           | NA                       | FAK                          | >100 | 8.76 ± 2.40 |

**Table** shows compound name, FDA approval status, compound class, target, average selectivity, and average IC₅₀ (μM). IC₅₀ Values are the mean of all cell lines that fulfill all criteria in the cancer grouping. Selectivity >100 indicates drug was “inactive” in HEK293T cells with efficacy <50%. No compounds were solely selective in cervical cancer.
Figure 4. Representative compounds with selective toxicity and nanomolar potency in a single cell line. Chemical structure and dose-response curves for (A, B) mycophenolate mofetil in PA-1 cells, (C, D) neritinib in TOV-21-G cells, (E, F) milciclib in TOV-21-G cells, and (G, H) LY2974455 in HeLa cells. See Table 4 for the full list of the most effective compounds for a single cell line.

Table 4. Single Cell Line Selective Compounds with Nanomolar Potency

| Compound Name       | FDA Approved | Compound Class                                      | Target                                | Avg SI | Avg IC₅₀ (µM) |
|---------------------|--------------|-----------------------------------------------------|---------------------------------------|--------|---------------|
| PA-1                |              |                                                     |                                       |        |               |
| Mycophenolate mofetil | Yes; 2008    | Immunosuppressant; prodrug                           | Inosine monophosphate dehydrogenase  | >100   | 0.631         |
| Pirarubicin         | No; in clinical trials | Antineoplastic; anthracine                          | DNA intercalater                      | 14.6   | 0.839         |
| Gimatecan           | No; in clinical trials | Antineoplastic; quinolone alakoid                    | Topoisomerase I                       | 12.5   | 0.0337        |
| PHA-793887          | No; in clinical trials | Antineoplastic                                       | CDK2/1/4/9, GSK3β                    | 12.3   | 0.194         |
| Doxorubicin         | Yes; 1993    | Antineoplastic; anthracine                           | DNA intercalater                      | 7.02   | 0.576         |
| TOV-21-G            |              |                                                     |                                       |        |               |
| Neratinib           | Yes; 2017    | Antineoplastic                                       | EGFR/Her2/Her4, P glycoprotein        | >100   | 0.619         |
| Milciclib           | No; in clinical trials | Antineoplastic                                       | CDK; tropomyosin receptor kinase      | 50.1   | 0.0897        |
| HeLa                |              |                                                     |                                       |        |               |
| LY2874455           | No; in clinical trials | Antineoplastic                                       | Pan-FGFR                              | 38.8   | 0.240         |
| AZD3463             | No           | Antineoplastic                                       | ALK/IGFR                              | 30.3   | 0.638         |
| NVP-TAE684          | No           | Antineoplastic                                       | ALK                                   | 28.0   | 0.835         |
| TAK 901             | No; completed clinical trials | Antineoplastic                                       | Aurora Kinase                         | 12.6   | 0.699         |

Table shows compound name, FDA approval status, compound class, target, average selectivity, and average IC₅₀ (µM). IC₅₀ values are the mean of the cell line shown. Selectivity >100 indicates drug was “inactive” in HEK293T cells with efficacy <50%.
This heterogeneity arises from differences in patient genetic background, patient age, tumor microenvironment, treatment regimen, and intrinsic resistance to drug therapy. In general, overall cancer incidence and death rates for women have been falling since the 1930s [2,48]. Ovarian cancer death rates peaked in 1970 at 10.6 deaths per 100,000 women and in 2015 stood at 7.1 deaths per 100,000 women [48]. Uterine cancer, including cervix and corpus, however, killed 37.6 women per 100,000 in 1932 and now stands at 7.1 deaths per 100,000 women [48]. The last few years have seen a slight rise in death rates for uterine cancers from 6.5 in 2009 to 7.1 in 2015 [48]. Ovarian cancer’s 5-year survival rates remain among the lowest survival rates of all female cancer types, rising slowly from 1975 (36% survival) to 2013 (47% survival) [49]. Furthermore, the development of selective chemotherapeutics that are selectively toxic to cancer cells is an ongoing mission in the cancer therapeutic research field. Understanding the differences and similarities in the chemotherapeutic responses of different gynecologic cancer cell types through chemotherapeutic profiling can aid in the development of safer, more effective therapies for these types of cancers. In this work, we have utilized a qHTS approach to profile the chemotherapeutic responses and selectivity of 11 gynecologic cancer cell lines to known chemotherapeutic molecules as well as other approved drugs and biologically active compounds.

We assessed the cytotoxicity of 7914 compounds consisting of approved drugs, drug candidates tested in clinical trials, and bioactive compounds in six ovarian, three cervical, and two placental cancer cell lines. Two Class I HDACis, mocetinostat and entinostat, were identified and confirmed as pan-gynecologic cancer inhibitors with high degrees of efficacy and selectivity (SI >100) in all three cancer groups. Interestingly, we did not find other HDACis to be as selective except for these two. Indeed, panobinostat, givinostat, and vorinostat, three other HDAC inhibitors, were found to be equally toxic to HEK 293T cells in our screens in addition to suppressing the 11 gynecologic cancer cell lines. HDACis prevent the removal of acetyl groups on histone lysines and, in effect, open chromatin structure to modulate gene expression [50]. Generally, epigenetic pathways are modified by HDACis to cause changes in the expression of genes which can induce cell-cycle arrest or apoptosis [51]. In addition to regulating histone acetylation, HDACis can inhibit the function of nonhistone effectors such as transcription factors to modulate gene expression.

In order to advance the compounds identified from a drug repurposing screen to potential clinical trials, the blood plasma concentration of the drug should be a few-fold higher than its IC₅₀ value or similar to or below its IC₅₀ value in the cells of the newly identified indication. We researched the human Cmax values of our most broadly potent compounds and compared them to the experimental IC₅₀ values in this study. In most cases, our experimental IC₅₀ is at or below the human plasma concentration, indicating that the effective drug concentration against the new indication is achievable in patients. Mocetinostat has a Cmax of approximately 21.4 μM at 10 mg/kg and 75.7 μM at 40 mg/kg in humans [52], while entinostat in humans reached a Cmax of 0.46 μM with 15 mg [53]. For mocetinostat, whose IC₅₀ in our work was found to be 2.76 ± 1.98 μM, this indicates that the Cmax is well above its anticancer activity. For entinostat, however, although the patient Cmax is significantly lower than the average IC₅₀ achieved in our study (7.11 ± 6.62 μM) for gynecologic cancers, its in vivo activity could possibly be achieved in higher doses or with compound structure-activity optimization. It is possible that the low toxicity of mocetinostat and entinostat is due to their specific HDAC isotype selectivity for certain HDACs. Both are class I HDAC inhibitors but exhibit varying IC₅₀s for specific HDACs. For example, mocetinostat was found to inhibit only HDAC 1/2/3/11 at low micromolar potency or below [54]. On the other hand, entinostat exhibited submicromolar potency against HDAC 1/2/3 only [55]. Their similar isotype selectivity profiles correlate with their similar in vivo effects against gynecologic cancers in our study. This HDAC isotype selectivity may be related to the drugs’ activity against the gynecologic cancer cell lines as HDAC 1/2/3 have been implicated in ovarian tumor malignancy and growth [56], while HDAC2 is overexpressed in cervical cancer carcinogenesis [57].

We also identified single cell line selective compounds with submicromolar potency and high selectivity for PA-1 (ovarian), TOV-21-G (ovarian), and HeLa (cervical), which could be due to their faster growth rates compared to other cancer cell lines and the cell cycle--interrupting nature of many compounds. Empirically, cells which cycle faster are more susceptible to interruptions of cell growth at different cycle stages [58]. However, certain drugs may act by disrupting specific cycle stage progression, i.e., G₀ to G₁ [59]. It is known that certain drugs are specific to certain phases. For example, 5-fluorouracil interrupts S phase by reducing thymidylate content for DNA synthesis [60], docetaxel interrupts M phase by preventing microtubule polymerization [61,62], and seliciclib interrupts G₁ phase by inhibiting CDKs 2/7/9 [63]. In this screen, PHA-793887 [64], a CDK2/1/4/9 inhibitor, was found to be potently toxic to PA-1 specifically, while milciclib [65], another CDK2 selective inhibitor, was specifically toxic to TOV-21-G with nanomolar potency. Both of these two CDK inhibitors suppress the cell growth phase.

The control cell line in this study, HEK 293T, is a normal human cell line originating from human embryonic kidney cells that is typically used as control cell line. The selectivity values determined in this study were relevant to the cytotoxicity of the compounds in HEK 293T cells. Given a different control line, the resulting selectivity may be different. The in vivo toxicity of compounds may also be different from the in vitro SI data. The

| Compound Name | FDA Approval | IC₅₀ (μM) | Cmax (μM) | Cell Lines Active | Reference |
|---------------|--------------|----------|-----------|------------------|-----------|
| Panobinostat (LBH589) | Yes; 2015 | 0.719 | 107.2-2.24 | 11 | [42,43] |
| Bortezomib | Yes; 2003 | 0.218 | 0.580 | 8 | [44] |
| Elacridomel (STA-4783) | No; in clinical trials | 0.283 | 1.32-12.84 | 6 | [45] |
| CEP-18770 (Delanzomib) | No; in clinical trials | 0.391 | 0.214-1.35 | 6 | [85] |
| BI-2536 | No; in clinical trials | 0.0397 | 1.61 | 4 | [86] |
| SN-38 | No; in clinical trials | 0.592 | 0.086 | 4 | [87] |
| Gedatolisib | No; in clinical trials | 0.80 | 16.2 | 4 | [88] |
| Gimatecan (No; clinical trials completed) | 0.275 ± 0.028 | 0.103-0.349 | 4 | [89] |
| Valosertib (No; in clinical trials) | 0.090 | 1.60-2.26 | 4 | [90] |

Table shows compound name, FDA approval status, average IC₅₀ (μM), Cmax, and the number of cell lines for which each compound is active.
selectivity reported here is for reference, and it should be noted that it cannot replace the data obtained from in vivo drug safety experiments and in clinical trials. We acknowledge the unequal numbers of lines for each cancer group (ovarian, cervical, and placental). Having fewer lines in one group will potentially increase the number of compounds that are pan-killers for that particular group. This is evident in the larger number of compounds that killed both placental lines as compared to the number of compounds that killed all six ovarian lines.

The results of this study warrant further investigation into the different responses cancers have to similar classes of compounds. Here, different HDAC inhibitors exhibit differential selectivity. This could possibly be due to differences in HDAC class specificity, with some inhibitors targeting class I HDACs preferentially to class II HDACs, for example [66]. Of the 19 compounds found to be pan-killers for all or some of the cancer groups, only three are FDA-approved drugs including Actinomycin D, neupent [67], and cyclosporin A [68]. Of these, only Actinomycin D is an FDA-approved antineoplastic, while neupent is an antifungal targeting Topoisomerase II and cyclosporin A is an immunosuppressant targeting calcineurin. Actinomycin D has been used as an alternative chemotherapeutic regimen for ovarian cancer [69] and GTD (placental cancer) [12]. As neupent disrupts mitotic activities, it has been researched as an antineoplastic agent in vivo against adenocarcinomic human alveolar basal epithelial (A549) cells and colorectal carcinoma (HCT116 cells) xenografts in combination with chlorpromazine [70] but is not used as an anticancer therapy in the clinic nor has it been used in the study of gynecologic cancer. Lastly, cyclosporin A showed no efficacy for platinum-resistant ovarian cancer in one Phase II trial [71]. In another trial studying drug-resistant gynecologic cancer, however, patients had an overall response rate of 29% after cyclosporin A treatment, and it was well tolerated [72]. Future work will seek to understand chemotherapeutic selectivity in more advanced models such as tumor spheroids, organoids, and in vivo xenograft models that could provide more physiologically relevant data on tumor killing.

Drug resistance to chemotherapy is a common cause for relapse and recurrence of many different types of cancers [73,74]. Platinum resistance is a common form of drug resistance in ovarian cancer with several suspected underlying causes including CDK expression, Akt signaling, and EGFR expression [75–77]. Our group recently published a set of compounds that were able to overcome cisplatin resistance in several platinum-resistant ovarian cancer cell lines when given alone and in combination with cisplatin [78]. The newly identified compounds in this study against gynecologic cancers can be used to further study the drugs’ synergistic effects with the SOC anticancer drugs. Therefore, some of our hits may be of interest in studying how to overcome drug resistance in ovarian, cervical, and placental cancers using the synergistic drug combination with the SOC anticancer drugs.

In conclusion, the compounds identified and confirmed in this drug repurposing screen and profiling can be used to further investigate their utility in the treatment of gynecological cancer, especially for multidrug-resistant cancer patients. We demonstrate here the variability and heterogeneous responses of gynecologic cancer cells to anticancer drugs that may be related to patient genetic background, age, intrinsic drug resistance, and cancer aggressiveness. Two HDAC inhibitors identified in this study, mocetinostat and entinostat, may have high clinical relevance and can be moved to clinical trials as bona fide gynecologic cancer therapeutics. Indeed, entinostat in combination with avelumab is already in Phase I/II clinical trials for epithelial ovarian cancer, peritoneal cancer, and fallopian tube cancer (ClinicalTrials.gov: NCT02915523). Likewise, despite its toxicity to HEK 293T cells, panobinostat may be further studied in in vivo experiments due to its extremely high potency in gynecologic cancers. In conclusion, the chemotherapeutic profiling in individual cancer cells is an effective method to reveal the best anticancer therapeutics that might be particularly useful for those cancers with multidrug resistance, poor prognosis, and survival rates.

**Methods**

**Reagents**

DMEM (11965092), penicillin/streptomycin (15140163), and TrypLE (12605010) were purchased from Life Technologies. FBS (SH30071.03) was purchased from HyClone (SH30071.03). ATPlite (6016739) was purchased from Perkin Elmer.

**Cell Lines**

The following cell lines were purchased from ATCC: CAOV-3 (ovarian adenocarcinoma; HTB-75), SK-OV-3 (ovarian adenocarcinoma; HTB-77), SW 626 (ovarian adenocarcinoma; HTB-78), ES-2 (ovarian clear cell carcinoma; CRL-1978), PA-1 (ovarian teratocarcinoma; CRL-1572), TOV-21G (ovarian clear cell carcinoma; CRL-11730), HeLa (cervical adenocarcinoma; CCL-2), Ca ski (cervical epidermoid carcinoma; CRL-1550), C-33 A (cervical carcinoma; HTB-31), JAR (placental choriocarcinoma; HTB-144), JEG-3 (placental choriocarcinoma; HTB-36), and HEK 293T (embryonic kidney fibroblast; CRL-3216).

**Cell Culture**

Cells were kept in cryovials frozen at −150°C and thawed quickly in a 37°C water bath. A total of 1.5 million cells were seeded into T-225 flasks and subcultured once using TrypLE before freezing down for future experiments. For all assays, cells were seeded at 1000 cells per well into white, solid-bottom 1536-well plates using a Thermo Fisher Multidrop Combi reagent dispenser.

**ATP Content Assay for Cell Viability, Growth Rate, and Positive Control Determination**

The ATPlite luminescence assay system assay kit was used to determine cell viability. The reagent was reconstituted and prepared as described by the manufacturer. To measure the cell death caused by the compounds, cells were cultured in 4 μl of media for 16 hours at 37°C with 5% CO₂ in assay plates, followed by the addition of DMSO or 16 SOC chemotherapeutic compounds dissolved in DMSO. SOC compounds were dosed at 11 concentrations (1:3 dilution) in quadruplicate from 57.5 μM to 0.977 nM using the automated Wako 1536 Pin Tool workstation and incubated at 37°C with 5% CO₂ for 24, 48, or 72 hours. Four microliters of ATPlite, the ATP monitoring reagent, was then added to each well of the assay plates using the Multidrop Combi reagent dispenser followed by incubation for 15 minutes at room temperature. The resulting luminescence was measured using the ViewLux plate reader. Data were normalized for each drug using the largest luminescence value as 100% full cell viability (0% cell killing) and to the smallest luminescence value 0% viability (100% cell killing).

**Large-Scale Compound Screening and Follow-Up**

A qHTS [79], in which each compound was assayed in five concentrations (0.092, 0.46, 2.3, 11.5, and 57.5 μM), was performed
for the primary compound screen using the NPC [80] and NPaCT drug libraries at NCATS. The OBGYN cancer and HEK 293T control cells were seeded into 1536-well assay plates at 1000 cells per 4 µl/well and incubated at 37°C in 5% CO2 for 48 hours. The ATPlile assay to determine the IC50 values for each compound was conducted as described above. Plates were processed on the fully integrated Kalypsys robotic system. Hits were selected from the primary screen for follow-up confirmation, dosed in triplicate at 11 concentrations (1:3 dilution) from 57.5 µM to 0.977 nM, and incubated for 48 hours, and the ATPlile assay was used to determine the IC50 values.

Statistical Analysis

Data analysis was performed using Microsoft Excel, and figures were generated using Prism Graphpad 7.0. In-house qHTS data normalization, correction, curve fitting, and classification were performed using custom programs developed at NCATS [81–83]. All data presented as mean ± S.D. unless otherwise stated.

Data Availability Statement

Data have been submitted to Pubchem. Primary Screen AID: 1345084. Confirmatory Screen AID: 1345085.

Credit Authorship Contribution Statement

K.G. and W.Z. wrote the manuscript and prepared figures. K.G., B.L., W.S., R.H., E.M.L., and W.Z. edited the manuscript. K.G., N.S., B.L., W.S., and W.H. conducted the experiments. J.T, C.K-T., and S.G.M. oversaw the automated screening machinery. K.G., T.X., and R.H. analyzed the data. W.S., X.C., and W.Z. conceived the initial concept for the paper.

Acknowledgements

We thank Dr. Matt Hall and colleagues at NCATS for their contribution of the independent HEK 293T toxicity confirmation data. This work was supported by the Intramural Research Program of the National Center for Advancing Translational Sciences, National Institutes of Health (W.Z.).

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.tranon.2018.11.016.

References

[1] Siegel R, Ma J, Zou Z, and Jemal A (2014). Cancer statistics, 2014. CA Cancer J Clin 64(1), 9–29.
[2] Miller K and Jamal A (2018). Cancer Facts and Figures 2018. American Cancer Society, 2018.
[3] Beavis AL, Gravitt PE, and Rosich AF (2017). Hysterecomy-corrected cervical cancer mortality rates reveal a larger racial disparity in the United States. Cancer 123(6), 1044–1050.
[4] Brown J, Naumann RW, Scedl M, and Schink J (2017). 15 years of progress in gestational trophoblastic disease: Scoring, standardization, and salvage. Gynecol Oncol 144(1), 200–207.
[5] Schedl MJ, Sebire NJ, and Berkowitz RS (2010). Gestational trophoblastic disease. Lancet 376(9742), 717–729.
[6] Sabininska B, Kielinska Z, and Zielinski J (1993). Chemotherapy combined with surgery in the treatment of gestational trophoblastic disease (GTD). Eur J Gynaecol Oncol 14(Suppl.), 146–151.
[7] Mural J (2017). Targeting DNA repair and replication stress in the treatment of ovarian cancer. Int J Clin Oncol 22(4), 619–628.
[8] Monk BJ, Minion LE, and Coleman RL (2016). Anti-angiogenic agents in ovarian cancer: past, present, and future. Ann Oncol 27(suppl.1), 133–139.
[9] Helm CW and States JC (2009). Enhancing the efficacy of cisplatin in ovarian cancer treatment - could arsenic have a role. J Ovarian Res 2, 2.
[10] Khan F, Everard J, Ahmed S, Coleman RE, Aitken M, and Hancock BW (2003). Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effects. J Cancer 89(12), 2197–2201.
[11] Alazzam M, Tidy J, Osborne R, Coleman R, Hancock BW, and Lawrie TA (2012). Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. Cochrane Database Syst Rev 12(4), CD008891.
[12] Deng L, Zhang J, T Wu, and Lawrie TA (2013). Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour. Cochrane Database Syst Rev (1) CD005196.
[13] Pakish JB and Jazaeri AA (2017). Immunotherapy in gynecologic cancers: are we there yet? Curr Treat Options Oncol 18(10), 59.
[14] Sjoquist KM, Martyn J, Edmondson RJ, and Friedlander ML (2011). The role of hormonal therapy in gynecological cancers-current status and future directions. Int J Gynecol Cancer 21(7), 1328–1333.
[15] Badisa RB, Darling-Redf SE, Joseph P, Cooperwood JS, Latinwo LM, and Goodman CB (2009). Selective cytotoxic activities of two novel synthetic drugs on human breast carcinoma MCF-7 cells. Anticancer Res 29(8), 2993–2996.
[16] El-Naggar NE-A, Deraz SF, Soliman HM, El-Deeb NM, and El-Fawy SM (2016). Purification, characterization, cytotoxicity and anticancer activities of L-asparginase, anti-cancer protein, from the newly isolated alkaliphilic Streptomyces fladiae FAAE-82. Sci Rep 6, 32926.
[17] Lopez-Lazaro M (2015). Two preclinical tests to evaluate anticancer activity and to help validate drug candidates for clinical trials. Oncovin 2(2), 91–98.
[18] Kaushik U, Aeri V, and Mir SR (2015). Cucurbitacins – an insight into medicinal leads from nature. Pharmacogn Rev 9(17), 12–18.
[19] Van Veggel M, Westerman E, and Hamberg P (2018). Clinical pharmacokinetics and pharmacodynamics of panobinostat. Clin Pharmacokinet 57(1), 21–29.
[20] Ganai SA (2016). Histone deacetylase inhibitor givinostat: the small-molecule drug has promise against therapeutically challenging haematological malignancies. J Chemother 28(4), 247–254.
[21] Feldman D and Koong AC (2007). Iresistin, a potent inhibitor of IRE1α and the unfolded protein response, is a hyposia-selective cytotoxin and impairs tumor growth. J Clin Oncol 25(18_suppl), 3514.
[22] Baumann P, Schneider L, Mandl-Webber S, Oduncu F, and Schmidmaier R (2012). Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anti-Cancer Drugs 23(1), 131–138.
[23] Iwamoto M, Friedman EJ, Sandhu P, Agrawal NG, Rubin EH, and Wagner JA (2013). Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor. Cancer Chemother Pharmacol 72(3), 493–508.
[24] Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G, Finke C, Mak CC, Mesa R, and Zhu H, et al. (2007). TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515LK mutations. Leukemia 21(8), 1658–1668.
[25] Ye S, Zhang J, Shen J, Gao Y, Li Y, Choy E, Cote G, Harmon D, Mankin H, and Gray NS, et al. (2016). NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function. Br J Pharmacol 173(3), 613–626.
[26] Wehrle J and von Babonoff N (2018). Ponatinib; a third-generation inhibitor for the treatment of CML. Recent Results Cancer Res 212, 109–118.
[27] Boumber Y, Younes A, and Garcia-Manero G (2011). Mocetinostat (Cd005196): a review of an isotype-specific histone deacetylase inhibitor. Expert Opin Investig Drugs 20(6), 823–829.
[28] Briere D, Sudhakar N, Woods DM, Hallin J, Engstrom LD, Aranda R, Chiang H, Sodre AL, Olson P, and Weber JS, et al. (2018). The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy. Cancer Immunol Immunother 67(3), 381–392.
[29] Batlevi CL, Grump M, Andreaics C, Rizziere D, Assouline SE, Fox S, van der Jagt RHC, Copeland A, Potvin D, and Chao R, et al. (2017). A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma. Br J Haematol 178(3), 434–441.
[30] Trapani D, Esposito A, Criscitiello C, Mazzarella L, Locatelli M, Minchella I, Minucci S, and Curigliano G (2017). Entinostat for the treatment of breast cancer. Expert Opin Investig Drugs 26(8), 965–971.
[31] Connolly RM, Rudek MA, and Pickard R (2017). Entinostat: a promising treatment option for patients with advanced breast cancer. Future Oncol 13(13), 1137–1148.
Lawrie TA, Alazzam M, Tidy J, Hancock BW, and Osborne R (2016). First-line chemotherapy in low-risk gestational trophoblastic neoplasia. *Cochrane Database Syst Rev* (6):CD007102.

Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, Jourdian NJ, Winton E, Silver RT, and Shouten HC, et al (2017). Janus kinase-2 inhibitor fedatinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. *Lancet Haematol* 4(7), e317–e324.

X Wu, Liu W, Cao Q, Chen C, Chen Z, Xu Z, Li W, Liu F, and Yao X (2014). Inhibition of Aurora B by CCT137690 sensitzies colorectal cells to radiotherapy. *J Exp Clin Cancer Res* 33, 13.

Bussel J, Arnold DM, Grossbard M, Mayer J, Trelinski J, Homenda W, Hellmann A, Windyga J, Sivceva L, and Khalafallah AA, et al (2018). Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. *Am J Hematol* 93(7), 921–930.

Jeong Y, You D, Kang HG, Yu J, Kim SW, Nam SJ, Lee JE, and Kim S (2018). Berberine suppresses fibrotic expression through inhibition of c-Jun phosphorylation in breast cancer cells. *J Breast Cancer* 21(1), 21–27.

Dong H, Wang N, Zhao L, and Lu F (2012). Berberine in the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. *Evid Based Complement Alternat Med* 2012, 591654.

Aghazadeh S and Yadzianparast R (2016). Mycophenolic acid potentiates HER2-overexpressing SKBR3 breast cancer cell line to induce apoptosis: involvement of AKT/FOXO1 and JAK2/STAT3 pathways. *Apoptosis* 21(11), 1302–1314.

Singh H, Walker AJ, Amir-Kordestani L, Cheng J, Tang S, Balcazar P, Barnett-Ringgold K, Palmyr TR, Cao X, and Zheng N, et al (2018). U.S. Food and Drug Administration approval: neratinib for the extended adjuvant treatment of early stage HER2-positive breast cancer. *Clin Cancer Res* 24(15), 3486–3491.

Weiss GJ, Hidalgo M, Borad MJ, Laheru D, Bissell MJ, Ray-Coquard I, Morice P, Lorusso D, Prat J, Oaknin A, and Pautier P (2018). The key role of epigenetics in human disease prevention and treatment. *Cancer* 124(6), 451–474.

Clive S, Woo MM, Nydam T, Kelly L, Squier M, and Kagan M (2012). Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients. *Cancer Chemother Pharmacol* 70(4), 513–522.

Sharma S, Beck J, Mita M, Paul S, Woo MM, Squier M, Gadabaw B, and Prince HM (2013). Phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors. *Invest New Drugs* 31(4), 974–985.

Michael M, Bang YJ, Park YS, Kang YK, Kim TM, Hamid O, Thornton D, Tate AA, and Zilberleyb I, et al (2007). Phase I clinical trial of STA-4783 in patients with relapsed/refractory hematologic malignancies. *J Clin Oncol* 25(24), 3834–3842.

Khalil HS, Mitev V, Vlaykova T, Cavicchi L, and Zhelev N (2015). Discovery and development of seliciclib. How systems biology approaches can lead to better drug performance. *BioRxiv*.

Ortol T and Sicinski P (2017). Cell cycle proteins as promising targets in cancer therapy. *Nat Rev Cancer* 17(2), 93–115.

Ray-Coquard I, Morice P, Lorusso D, Prat J, Oaknin A, and Pautier P (2018). A prospective study of intravenous dactinomycin in patients with advanced solid malignancies. *J Biomed Biotech* 2018, 2026–2094.

Huang BH, Laban M, Leung CHW, Lee I, Lee CK, Salto-Tellez M, Raja GJ, and Hooi SC (2005). Inhibition of histone deacetylase 2 increases apoptosis and p21cip1/waf1 expression, independent of histone deacetylation. *1 Cell Death Differ* 12, 395–409.

Henderson-D’Arazza H, Chauvin C, and Brennan B, et al (2005). Pharmacokinetics of dactinomycin in children with cancer. *J Pediatr Hematol Oncol* 27(3), 153–159.

Borghi D, Casale E, and Croci V, et al (2010). Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing. *Biorg Med Chem* 18(5), 1844–1853.

Weiss J and Newton PK (2018). Optimizing chemo-scheduling based on tumor growth rates. *bioRxiv*.

Doronin VA, Schmidt A, Hulin C, Leleu X, and Esseltine D-L, et al (2012). Phase I study of the safety, tolerability and pharmacokinetics of MGCD0103, a novel isotype-specific histone deacetylase inhibitor, in patients with advanced cancer. *Pharmacology* 83(2), 131–134.

Ordentlich P, Cruickshank S, and Kunkel L, et al (2016). ENGAGE-501: phase 1B, randomized, open-label dose escalation and safety study of panobinostat in patients with relapsed/refractory multiple myeloma. *Haematologica* 101(8), 968–975.

Bennett JR, Heerema NA, Wadler M, McFarland N, Strickler JG, and Davis S (2015). First-line chemotherapy or hematopoietic stem cell transplant. *Blood* 126(3), 465–469.

Lauffer BE, Mintzer R, Fong R, Mukund S, Tam C, Zilberleyb I, et al (2007). Phase I clinical trial of STA-4783 in patients with relapsed/refractory hematologic malignancies. *J Clin Oncol* 25(24), 3834–3842.

Henderson V, Angeli P, Zama C, Kosiorek C, Choudhury A, and Vaz F (2017). A pediatric patient population: a United Kingdom Children’s Cancer Study Group Study. *Clin Cancer Res* 11(16), 5893–5899.

National Center for Health Statistics (NCHS), C.f.D.C.a.P (2017). *Trends in death rates, 1990-2015*. Available from: https://www.cdc.gov/nchs/nvss/nvss_deaths.htm.

Institute, N.C (2017). Surveillance, Epidemiology, and End Results (SEER) 9 registries; 2017 [cited 2018 05–02].

Suraweera A, O’Byrne KJ, and Richard DJ (2018). Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACs. *Front Oncol* 8, 92.

Feinberg AP (2018). The key role of epigenetics in human disease prevention and mitigation. *N Engl J Med* 378(14), 1323–1334.

Spence S, Deurinck M, H Ju, Traebert M, McLean L, Marlowe J, et al (2013). ENGAGE-501: phase 2 study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma. *Haematologica* 108(1), 968–975.

Borghi D, Casale E, and Croci V, et al (2010). Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing. *Biorg Med Chem* 18(5), 1844–1853.

Beaucourt PR, Chargui NS, and Wasan KM (2007). Cyclosporine A: a review of current oral and intravenous delivery systems. *Drug Des Ind Pharm* 33(3), 211–220.

Ray-Coquard I, Moreau P, Prat J, Oaknin A, and Pautier P (2018). A prospective study of intravenous pentamidine for PJP prophylaxis in adult patients undergoing intensive chemotherapy or hematopoietic stem cell transplant. *Bone Marrow Transplant* 53(3), 300–306.

Ray-Coquard I, Mornet P, Lorusso D, Prat J, Oaknin A, and Pautier P (2018). Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 23(7), 20–26.

Lee MS, Johansen L, Zhang Y, Wilson A, Keegan M, Avery W, Elliott P, Borisy AA, and Keith CT (2007). The novel combination of chlorpromazine and
pentamidine exerts synergistic antiproliferative effects through dual mitotic action. *Cancer Res* **67**(23):11359.

[71] Manetta A, Blessing JA, and Hurteau JA (1998). Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a phase II study of the gynecologic oncology group. *Gynecol Oncol* **68**(1), 45–46.

[72] Sood AK, Sorosky JL, Squatrito RC, Skilling JS, Anderson B, and Buller RE (1999). Cyclosporin A reverses chemoresistance in patients with gynecologic malignancies. *Neoplasia* **1**(2), 118–122.

[73] Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, and Sarkar S (2014). Drug resistance in cancer: an overview. *Cancer* **63**(3), 1769–1792.

[74] Gottesman MM (2002). Mechanisms of cancer drug resistance. *Annu Rev Med* **53**, 615–627.

[75] Guffanti F, Fratelli M, Ganzinelli M, Bolis M, Ricci F, Bizzaro F, Chila R, Sina FP, Fruscio R, and Lupia M, et al (2018). Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenographs. *Oncotarget* **9**(37), 24707–24717.

[76] Kawaguchi H, Terai Y, Tanabe A, Sasaki H, Takai M, Fujiwara S, Ashihara K, Tanaka Y, Tanaka T, and Tsunetoh S, et al (2014). Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer. *J Ovarian Res* **7**, 38.

[77] Satpathy M, Mezencev R, Wang L, and McDonald JF (2016). Targeted in vivo delivery of EGFR siRNA inhibits ovarian cancer growth and enhances drug sensitivity. *Sci Rep* **6**(5618).

[78] Sima N, Sun W, Gorshkov K, Shen M, Huang W, Zhu W, Xie X, Zheng W, and Cheng X (2018). Small molecules identified from a quantitative drug combinatorial screen resensitize cisplatin’s response in drug-resistant ovarian cancer cells. *Transl Oncol* **11**(4), 1053–1064.

[79] Inglese J, Auld DS, Jadhav A, Johnson RL, Simeonov A, Yasgar A, Zheng W, and Austin CP (2006). Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. *Proc Natl Acad Sci U S A* **103**(31), 11473–11478.

[80] Huang BH, Laban M, Leung CHW, Lee L, Lee CK, Salto-Tellez M, Raju GC, and Hooi SC (2011). The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. *Sci Transl Med* **3**(80):80sr16.

[81] Southall NT, et al (2009). In: Seethala R, Zhang L, editors. Enabling the large scale analysis of quantitative high throughput screening data, in Handbook of Drug Screening. New York: Taylor and Francis; 2009. p. 442–463.

[82] Wang Y and Huang R (2016). In: Zhu H, Xia M, editors. Correction of microplate data from high throughput screening, in High-Throughput Screening Assays in Toxicology. Humana Press; 2016.

[83] Wang Y, Jadhav A, Southall N, Huang R, and Nguyen D-T (2010). A grid algorithm for high throughput fitting of dose-response curve data. *Curr Chem Genomics* **4**, 57–66.

[84] Lee OW, Austin SM, Gamma MR, Cheef DM, Lee DT, Wilson KM, Johnson JM, Travers JC, Braisted JC, and Guha R, et al (2018). Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. *bioRxiv*; 2018.

[85] Gallerrani E, Zucchetti M, Brunelli D, Marangon E, Noberasco C, Hess D, Delmonte A, Martinelli G, Bohm S, and Driessen C, et al (2013). A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. *Eur J Cancer* **49**(2), 290–296.

[86] Mross K, Frost A, Steinbild S, Hedbom S, Rentschler J, Kaiser R, Rouytre N, Trommasher D, Hoeel CE, and Munzert G (2008). Phase I Dose escalation and pharmacokinetic study of BI 2536, a novel polo-like kinase 1 inhibitor, in patients with advanced solid tumors. *J Clin Oncol* **26**(34), 5511–5517.

[87] Satoh T, Yasui H, Muro K, Komatsu Y, Sameshima S, Yamaguchi K, and Sugihara K (2013). Pharmacokinetic assessment of irinotecan, SN-38, and SN-38-glucuronide: a substudy of the FIRIS Study. *Anticancer Res* **33**(9), 3845–3853.

[88] Shapiro GI, Bell-McGuinn KM, Molina JR, Bendell J, Spicer J, Kwak EL, Pandya SS, Milham R, Borzillo G, and Pierce KJ, et al (2015). First-in-human study of PF-05212384 (PKI-587), a small-molecule, intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer. *Cancer Sci* **106**(3), 385–391.

[89] Frapolli R, Zucchetti M, Sessa C, Marsoni S, Viganò L, Locatelli A, Rulli E, Compagnoni A, Bello E, and Pisano C, et al (2010). Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels. *Eur J Cancer* **46**(3), 505–516.

[90] Kobayashi Y, Yamachi T, Kiyoi H, Sakura T, Hata T, Ando K, Watabe A, Harada A, Taube T, and Miyazaki Y, et al (2015). Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia. *Cancer Sci* **106**(11), 1590–1595.